Azitra, Inc. (AZTR)
Oxford Ledge is still expanding full research coverage of AZTR. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Azitra develops genetically engineered bacterial therapies for skin diseases using proprietary microbial screening and artificial intelligence technologies.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-17
- 8-K Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-06-16
- 8-K Other material event; Financial statements and exhibits 2026-06-04
- 8-K Other material event; Financial statements and exhibits 2026-05-27
- S-1 IPO / securities registration statement 2026-05-21
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for AZTR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AZTR in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.